FindTrial
Sign In

INDUCTIVE CHEMIOTHERAPY WITH CISPLATIN AND GEMTABICINE FOLLOWED BY TOMOTHERAPY WITH METABOLIC GUIDE FOR THE TREATMENT OF PATIENTS AFFECTED BY PULMONARY CARCINOMA (NOT SMALL CELL)IN LOCALLY ADVANCED STAGE: PILOT STUDY OF PHASE II

INDUCTIVE CHEMIOTHERAPY WITH CISPLATIN AND GEMTABICINE FOLLOWED BY TOMOTHERAPY WITH METABOLIC GUIDE FOR THE TREATMENT OF PATIENTS AFFECTED BY PULMONARY CARCINOMA (NOT SMALL CELL)IN LOCALLY ADVANCED STAGE: PILOT STUDY OF PHASE II

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-003765-32-IT
Enrollment
Unknown
Registered
2008-01-08
Start date
2004-12-01
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

INDUCTIVE CHEMIOTERAPY MedDRA version: 6.1 Level: PT Classification code 10029522

Interventions

Pharmaceutical Form: Solution for infusion INN or Proposed INN: Cisplatin CAS Number: 15663-27-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical

Sponsors

OSPEDALE S. RAFFAELE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026